Vaccine designed to ‘intercept’ pancreatic cancer induces durable responses

An investigational vaccine that targets common KRAS mutations induced durable immune responses among individuals at high risk for pancreatic cancer, results of a phase 1 clinical trial showed.Eighteen of 20 participants achieved KRAS-specific T-cell responses. Several individuals had either complete radiographic resolution or regression of pancreatic cysts, and none developed pancreatic cancer by